Abemaciclib & Breast Cancer: Dose Adjustment Shows Promise
- CHICAGO—A recent phase 2 trial suggests a potential strategy for improving outcomes in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.
- The study focused on patients with stage II and III breast cancer.
- “We hope this is a successful strategy that providers can use in clinic that will allow patients to get the maximum benefit out of abemaciclib,” Mayer said.
A recent phase 2 trial offers a promising strategy for abemaciclib, indicating a potential boost in treatment outcomes for early-stage hormone receptor-positive, HER2-negative breast cancer patients. The TRADE study, discussed at the ASCO Annual Meeting, reveals that 70% of participants maintained the target abemaciclib dose. Discover how this dose escalation approach could maximize benefits for patients. News Directory 3 brings you the latest updates on this critically important research. Researchers are hopeful that these findings will inform clinical practice,possibly leading to better outcomes through optimized abemaciclib dosage. Explore the findings on abemaciclib adn breast cancer, and consider the implications for future treatment strategies. Discover what’s next …
study Shows Promise for Abemaciclib Dose Escalation in Early Breast Cancer
Updated June 15, 2025
CHICAGO—A recent phase 2 trial suggests a potential strategy for improving outcomes in patients with early-stage hormone receptor-positive, HER2-negative breast cancer. The TRADE study, presented at the ASCO Annual Meeting, investigated the tolerability of abemaciclib (Verzenio, Eli Lilly & Co.) dose escalation.Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discussed the findings in a video report.
The study focused on patients with stage II and III breast cancer. Results indicated that 70% of participants were able to achieve and maintain the target dose of 150 mg twice daily by the 12-week mark, demonstrating the feasibility of this approach to abemaciclib dose escalation.
“We hope this is a successful strategy that providers can use in clinic that will allow patients to get the maximum benefit out of abemaciclib,” Mayer said.
What’s next
Researchers hope these findings will inform clinical practise, enabling more patients to receive the optimal dose of abemaciclib for improved treatment outcomes in early-stage breast cancer. Further studies may explore long-term efficacy and safety.